A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer

2014 ◽  
Vol 50 (1) ◽  
pp. 40-49 ◽  
Author(s):  
A. Lange ◽  
A. Prenzler ◽  
M. Frank ◽  
M. Kirstein ◽  
A. Vogel ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Monoclonal Antibodies ◽  
Cost Effectiveness ◽  
Metastatic Colorectal Cancer

Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies

2019 ◽  
Vol 73 ◽  
pp. 41-53 ◽  
Author(s):  
Gianluca Mauri ◽  
Elio Gregory Pizzutilo ◽  
Alessio Amatu ◽  
Katia Bencardino ◽  
Laura Palmeri ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Monoclonal Antibodies ◽  
Metastatic Colorectal Cancer

scholarly journals Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study

2015 ◽  
Vol 16 (11) ◽  
pp. 1577-1584 ◽  
Author(s):  
Feng Wen ◽  
Yu Yang ◽  
Pengfei Zhang ◽  
Jian Zhang ◽  
Jing Zhou ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibodies ◽  
Cost Effectiveness ◽  
Metastatic Colorectal Cancer

First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis

2015 ◽  
Vol 96 (1) ◽  
pp. 156-166 ◽  
Author(s):  
Filippo Pietrantonio ◽  
Chiara Cremolini ◽  
Fausto Petrelli ◽  
Maria Di Bartolomeo ◽  
Fotios Loupakis ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Monoclonal Antibodies ◽  
Metastatic Colorectal Cancer ◽  
Meta Analysis ◽  
Wild Type ◽  
First Line

Comparative effectiveness and safety of monoclonal antibodies (bevacizumab, cetuximab and panitumumab) in the treatment of metastatic colorectal cancer: Systematic review and metanalysis.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15008-e15008
Author(s):  
Wania Cristina Silva ◽  
Ellias Magalhaes Abreu Lima ◽  
Vânia Eloísa Araújo ◽  
Jéssica Barreto Ribeiro Santos ◽  
Michael Ruberson Ribeiro Silva ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Monoclonal Antibodies ◽  
Metastatic Colorectal Cancer ◽  
Methodological Quality ◽  
Progression Free Survival ◽  
Cochrane Library ◽  
Safety Outcome ◽  
Newcastle Ottawa Scale ◽  
Ottawa Scale

e15008 Background: Biological agents have presented variable results in the treatment of metastatic colorectal cancer. This study aim to evaluate the effectiveness and safety of the monoclonal antibodies bevacizumab, cetuximab and panitumumab associated or not to chemotherapy in this scenario. Methods: A systematic review and metanaysis was performed based on observational cohort studies published in the following databases: MEDLINE/ Pubmed, LILACS, COCHRANE Library and EMBASE, up to march 2016. The effectiveness outcomes assessed in this trial were overall survival (OS), progression free survival (PFS), pos-progression survival (PPS), response rate based on RECIST criteria and metastasectomy rate. The safety outcome assessed was adverse events. Review Manager 5.3 software was used to perform the data metanalysis and the Newcastle-Ottawa scale evaluated the methodological quality of the observational trials included. Results: 16 trials were included in this metanalysis, 11 evaluating effectiveness and 8 assessing safety. Their methodological quality were considered moderate according to the Newcastle-Ottawa Scale. Basically, this study compared bevacizumab based therapies with no bevacizumab based therapies, once there was no enough data regarding cetuximab and panitumumab. Overall, the group treated with bevacizumab based therapies did better than those in the no bevacizumab group, with OS mean difference (MD) of 4,41 (95% CI 1.75 to 7.07; p = 0.001; I² = 86%) and PFS MD of 3.19 (95% CI 0.42 to 5.96; p = 0,02 I² = 96%). The PPS MD was also statistically significant (MD = 5.90; 95% CI 2.59 to 9.21; p = 0,0005; I² = 82%). When safety was the outcome concerned, the group treated with bevacizumab had more hypertension and gastrointestinal perforation. There was no statistical difference between the groups regarding others side effects. Conclusions: This study showed a potential benefit in using bevacizumab as a part of the treatment of mCRC. Bevacizumab improved PFS, OS and PPS and these differences were statistically significant. However, the drug also increased treatment related toxicities.

scholarly journals Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis

BioDrugs ◽  
2018 ◽  
Vol 32 (6) ◽  
pp. 585-606 ◽  
Author(s):  
Wânia Cristina da Silva ◽  
Vânia Eloisa de Araujo ◽  
Ellias Magalhães e Abreu Lima ◽  
Jessica Barreto Ribeiro dos Santos ◽  
Michael Ruberson Ribeiro da Silva ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Monoclonal Antibodies ◽  
Metastatic Colorectal Cancer ◽  
Comparative Effectiveness ◽  
Meta Analysis
Sign in / Sign up

Export Citation Format

Share Document